Evidence map›Paper›PMID 25762001›Full record

ArticleStem cells translational medicine2015

Expression of coxsackievirus and adenovirus receptor separates hematopoietic and cardiac progenitor cells in fetal liver kinase 1-expressing mesoderm.

Katsuhisa Tashiro, Nobue Hirata, Atsumasa Okada, Tomoko Yamaguchi, Kazuo Takayama, Hiroyuki Mizuguchi, Kenji Kawabata

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Katsuhisa TashiroLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Nobue HirataLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Atsumasa OkadaLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Tomoko YamaguchiLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Kazuo TakayamaLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Hiroyuki MizuguchiLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
Kenji KawabataLaboratory of Stem Cell Regulation and Laboratory of Hepatocyte Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Laboratory of Biochemistry and Molecular Biology, iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, and Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan kawabata@nibio.go.jp.
National Institute of Biomedical Innovation, Health and Nutrition · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In developing embryos or in vitro differentiation cultures using pluripotent stem cells (PSCs), such as embryonic stem cells and induced pluripotent stem cells, fetal liver kinase 1 (Flk1)-expressing mesodermal cells are thought to be a heterogeneous population that includes hematopoietic progenitors, endothelial progenitors, and cardiac progenitors. However, information on cell surface markers for separating these progenitors in Flk1⁺ cells is currently limited. In the present study, we show that distinct types of progenitor cells in Flk1⁺ cells could be separated according to the expression of coxsackievirus and adenovirus receptor (CAR, also known as CXADR), a tight junction component molecule. We found that mouse and human PSC- and mouse embryo-derived Flk1⁺ cells could be subdivided into Flk1⁺CAR⁺ cells and Flk1⁺CAR⁻ cells. The progenitor cells with cardiac potential were almost entirely restricted to Flk1⁺CAR⁺ cells, and Flk1⁺CAR⁻ cells efficiently differentiated into hematopoietic cells. Endothelial differentiation potential was observed in both populations. Furthermore, from the expression of CAR, Flk1, and platelet-derived growth factor receptor-α (PDGFRα), Flk1⁺ cells could be separated into three populations (Flk1⁺PDGFRα⁻ CAR⁻ cells, Flk1⁺PDGFRα⁻CAR⁺ cells, and Flk1⁺PDGFRα⁺CAR⁺ cells). Flk1⁺PDGFRα⁺ cells and Flk1⁺PDGFRα⁻ cells have been reported as cardiac and hematopoietic progenitor cells, respectively. We identified a novel population (Flk1⁺PDGFRα⁻ CAR⁺ cells) with the potential to differentiate into not only hematopoietic cells and endothelial cells but also cardiomyocytes. Our findings indicate that CAR would be a novel and prominent marker for separating PSC- and embryo-derived Flk1⁺ mesodermal cells with distinct differentiation potentials.

Indexed as

AnimalsCell DifferentiationCell LineageEmbryonic Stem CellsEndothelial CellsGene Expression Regulation, ViralHematopoietic Stem CellsHumansMesodermMiceReceptors, Virusadenovirus receptorcoxsackievirus B receptorReceptors, VirusCardiomyocytesCoxsackievirus and adenovirus receptorDifferentiationFetal liver kinase 1Hematopoietic cellsMesoderm

Identifiers

PMID25762001
PMCPMC4414217
OpenAlexW2031410511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.